Success Stories: A Research Fellow in the Field of Biomedical Sciences Secures NIW Approval with our Constant Help. Thanks to Premium Processing, She even Secured EB1-A Approval in less than 3 months only.
Client’s Testimonial:
“Thank You for the message. I am grateful for your efforts to make it happen.”
On March 23rd, 2023 and April 17th, 2023, we received another EB-2 NIW (National Interest Waiver) approval and EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Biomedical Sciences (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: March 23rd, 2023 (NIW) and April 17th, 2023 (EB1A)
Processing Time: 3 months, 21 days (NIW) and 2 months, 22 days (EB1A) (Premium Processing Requested)
Case Summary:
An EB-2 NIW (National Interest Waiver) petition approval was granted to a research fellow with a Ph.D. in applied biology from India. Before starting with a client-attorney agreement, the North American Immigration Law Group judged her provided credentials to determine her NIW’s success. We asserted that we could lead her to obtain the national interest waiver after a thorough evaluation only.
Our team thus, followed a proficient process of analyzing her background, paperwork, and the associated evidence, and were then only confident that they were enough to persuade USCIS and get our client the NIW approval.
Since, the method of obtaining a green card involves two steps, that is, filing an I-140 petition and an I-485 application, our client even retained us for another I-140 petition under the EB-1A (Alien of Extraordinary Ability) visa category as well.
We highlighted the following aspects to make her case a success:
- The 13 peer-reviewed scientific articles she published in some of the most discerning, high-impact journals in the field of biomedical sciences.
- A splendid record of obtaining 383 citations in other peer-reviewed journal articles.
- Cited by researchers in at least 37 countries.
- Also been invited to review and evaluate the work of her peers no fewer than 11 times, serving as major evidence of her supremacy in the field.
Our client’s study has even received funding from the Department of Biotechnology-the Government of India, the Indian Council of Medical Research, and the German Research Foundation. This funding serves as clear evidence of the merit of her work in glucose-dependent insulin secretion and its widespread implications for treating diabetes.
Furthermore, considering the impactful articles our client has published, the numerous citations her work has attained, and the funding it has been granted, has proven her to be a prominent and influential member of the field, having provided many important and influential contributions that are addressing the needs of both the academic and greater community.
Also, the following statement is excerpted from one of the four recommendation letters submitted:
“[Client’s] work is essential to earn the United States a place at the forefront of diagnostic methods targeting debilitating childhood leukemia…[Client] has previously investigated molecular markers of JMML to identify poor and favorable prognostic sample subsets. She found that DNA methylation is an optimal marker to predict patients' overall survival and the probability of relapse. [Client’s] novel prognosis method is relevant to improving JMML patient outcomes in the United States, and it provides an opportunity for the nation to take the lead in diagnosing this childhood disease.”
All of this evidence is fully supported and corroborated by letters from internationally recognized experts in the field who have used our client’s work in their research endeavors and attest to its influence and major significance. The totality of this evidence shows that our client is one of that small percentage who has risen to the very top of her field and has sustained both national and international acclaim.
She is therefore fully qualified as an individual of extraordinary ability in her field of expertise.
We are thrilled that our team was once again successful in persuading USCIS of the importance of our client’s research in the United States. Thus, she was granted not only EB1-A approval in less than 3 months only (thanks to Premium Processing) but also NIW. We would sincerely like to wish her success in her future endeavors.